In his new book, Theodore Schwartz, MD, immerses readers in the story of brain surgery
No adverse liver effects seen with elinzanetant in OASIS 3 trial
Hazards for radiographic PFS, OS reduced by 31% with enzalutamide plus Ra-223
Facilities neglect social responsibility standards, patients and clinicians said
POD1UM-303/InterAACT 2 data also trend in the direction of better overall survival
Meta-analysis of 23 randomized trials showed lower HOMA-IR
Where medicine is all fun and games
Members skeptical of verification process, concerned about patient safety
Even if ketamine isn't as addictive as opioids, widespread use can still pose problems
At least seven kids have died while playing football so far this year
You passed medical training, now see if you can pass our weekly quiz
Multi-step, condition-based, and doctor-reviewed resource library for physicians and their patients.See All Medical Journeys >
But combination may be appropriate for shrinking tumors before surgery
Second-line T-DXd best option in patients with and without intracranial activity, experts says
Also in TTHealthWatch: time from approval to reimbursement for new drugs
38% of patients treated with IL-13 blocker achieved clear or almost-clear skin at 16 weeks
Advisory committee members put their foot down on shaky science
More noteworthy research from the EASD 2024 meeting
Other studies looked at steroids for kids with pneumonia and a link between asthma and fertility
Rule would streamline criteria for organ donation from donors with HIV to recipients with HIV
Addressing shortcomings will require moving "beyond clinical care," agency says
Data support that ICI rechallenge should be discouraged in patients with advanced RCC
Despite renewed spotlight on menopause, use by insured still hasn't rebounded
Three-day intervention boosted time spent in normal glucose range
"Mind-boggling" effects in small group with Leber congenital amaurosis 1, expert says
Inquiries are "slow, insufficiently staffed," and get pushback from hospitals, said one expert
Steward CEO, Ralph de la Torre, MD, was a "no-show" at hearing, despite subpoena
Health news and commentary gathered by 乌鸦传媒視頻 staff
乌鸦传媒視頻 reporters offer further insights into these recently covered topics
One negative trial in the phase III PROMIS program blamed squarely on the COVID-19 pandemic
乌鸦传媒視頻 reporters offer further insights into these recently covered topics
Also in TTHealthWatch: beta-blockers after MI
A discussion with the former CEO of the Bill & Melinda Gates Foundation
Three healthcare professionals describe when they were gaslit by their peers
Team USA's chief medical officer also discusses what he learned in Paris to prepare for next time
This newly approved testing modality brings challenges and opportunities
Just because something is legal doesn't mean it's ethical
Unequal access threatens to worsen disparities
The potential benefits of CAR T-cell therapies still far outweigh the risks